IGF::OT::IGF: SBIR PHASE II, TOPIC 331: OPTICAL BIOSENSOR FOR REAL-TIME ASSESSMENT OF TUMOR CELLULARITY DURING CORE NEEDLE BIOPSY PROCEDURES.

IGF::OT::IGF：SBIR 第二阶段，主题 331：用于在芯针活检过程中实时评估肿瘤细胞性的光学生物传感器。

• 批准号: 9360347
• 负责人: NICUSOR IFTIMIA
• 金额: $ 149.97万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2018-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9360347
• 关键词: Address; Animal Cancer Model; Biopsy; Biosensor; Cellularity; Clinical; Core Biopsy; Detection; Fibrosis; Goals; Inflammation; Location; Necrosis; Needle biopsy procedure; Optics; Phase; Physicians; Resolution; Small Business Innovation Research Grant; Technology; Time; Translating; Ultrasonography; Validation; commercialization; improved; new technology; novel; programs; radiologist; skills; success; tumor

The long term goal of this program is to develop and translate to clinical use a novel technology that will help interventional radiologists to improve the success rate of the core needle biopsy procedures. Although ultrasound or CT are used to identify tumor location and thus to guide biopsy needle insertion, these technologies do not provide the necessary resolution to determine tumor cellularity. It is known that many tumors are heterogeneous (mixture of viable tumor, necrosis, fibrosis and inflammation), and therefore interventional radiologists encounter serious challenges when performing biopsies due to the inability of collecting sufficient or adequate material for histological analysis. As a result, biopsy success varies within a large range, from 65 to 95%, depending on the physician skills, tumor size, and biopsy location.

该计划的长期目标是开发并转化为临床使用一种新型技术，该技术将有助于介入放射学家提高核心针头活检程序的成功率。尽管超声或CT用于识别肿瘤位置并因此引导活检针头插入，但这些技术并未提供确定肿瘤细胞性的必要分辨率。众所周知，许多肿瘤是异质的（可行肿瘤的混合物，坏死，纤维化和炎症的混合物），因此，由于无法收集足够或足够的材料进行组织学分析，进行活检时，介入放射学家在进行活检时会遇到严重的挑战。结果，取决于医师技能，肿瘤大小和活检位置，活检成功范围内从65％到95％。